One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes
Yasmina Abakkouy, Isabelle Cleynen
doi : 10.1093/ecco-jcc/jjab021
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 877–878
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N Viget, Y Zabana, S Vavricka on behalf of the European Crohn’s and Colitis Organisation [ECCO]
doi : 10.1093/ecco-jcc/jjab052
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 879–913
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
Kevin L Winthrop, Edward V Loftus, Jr, Daniel C Baumgart, Walter Reinisch, Chudy I Nduaka, Nervin Lawendy, Gary Chan, Rajiv Mundayat, Gary S Friedman, Leonardo Salese, Andrew J Thorpe, Chinyu Su
doi : 10.1093/ecco-jcc/jjaa233
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 914–929
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes.
Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes
M D Voskuil, L M Spekhorst, K W J van der Sloot, B H Jansen, G Dijkstra, C J van der Woude, F Hoentjen, M J Pierik, A E van der Meulen, N K H de Boer, M L?wenberg, B Oldenburg, E A M Festen, R K Weersma Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis
doi : 10.1093/ecco-jcc/jjaa223
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 930–937
Inflammatory bowel disease [IBD] phenotypes are very heterogeneous between patients, and current clinical and molecular classifications do not accurately predict the course that IBD will take over time. Genetic determinants of disease phenotypes remain largely unknown but could aid drug development and allow for personalised management. We used genetic risk scores [GRS] to disentangle the genetic contributions to IBD phenotypes.
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
Walter Reinisch, William J Sandborn, Silvio Danese, Xavier Hébuterne, Maria K?opocka, Dino Tarabar, Tom?? Va??sek, Milo? Gregu?, Paul A Hellstern, Joo Sung Kim, Miles P Sparrow, Kenneth J Gorelick, Michael Hoy, Martina Goetsch, Caleb Bliss, Charu Gupta, Fabio Cataldi, Séverine Vermeire
doi : 10.1093/ecco-jcc/jjab023
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 938–949
Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II.
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Séverine Vermeire, Michael Chiorean, Juli?n Panés, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E Sands, Krisztina Lazin, Preston Klassen, Snehal U Naik, Christopher H Cabell, William J Sandborn
doi : 10.1093/ecco-jcc/jjab016
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 950–959
Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind, placebo-controlled trial in adults with moderately-to-severely active ulcerative colitis [OASIS], etrasimod 2 mg provided significant benefit versus placebo and was generally well tolerated. This open-label extension [OLE] evaluated safety and efficacy of etrasimod for up to 52 weeks.
Pre-pouch Ileitis is Associated with Development of Crohn’s Disease-like Complications and Pouch Failure
Gaurav Syal, Ron Shemtov, Nirupama Bonthala, Eric A Vasiliauskas, Edward J Feldman, Karen Zaghiyan, Christina Y Ha, Dermot P B McGovern, Stephan R Targan, Gil Y Melmed, Phillip R Fleshner
doi : 10.1093/ecco-jcc/jjaa251
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 960–968
It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone.
Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study
Iril Lovise Monstad, Inger Camilla Solberg, Milada Cvancarova, Oistein Hovde, Magne Henriksen, Gert Huppertz-Hauss, Eva Gunther, Bj?rn Allan Moum, Njaal Stray, Morten Vatn, Ole Hoie, J?rgen Jahnsen
doi : 10.1093/ecco-jcc/jjaa232
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 969–979
The long-term course of ulcerative colitis [UC] is difficult to predict. Mortality, colectomy, cancer, and hospitalisation represent hard outcomes of disease. Moreover, knowledge on the risk of relapses and need for potent medication add important information about living with UC. We aimed to evaluate the course and prognosis of UC during the first 20 years after diagnosis, and to identify early prognostic risk factors.
Women’s Earnings are more Affected by Inflammatory Bowel Disease than Men’s: A Register-Based Swedish Cohort Study
?sa H Everhov, Gustaf Bruze, Jonas S?derling, Johan Askling, Jonas Halfvarson, Karin Westberg, Petter Malmborg, Caroline Nordenvall, Jonas F Ludvigsson, Ola Olén
doi : 10.1093/ecco-jcc/jjaa238
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 980–987
Patients with inflammatory bowel disease [IBD] are subject to more work disability than the general population. We aimed to estimate the monetary cost of IBD for the individual through assessment of earnings in relation to diagnosis.
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations
Nathalie Van den Berghe, Bram Verstockt, Ann Gils, Jo?o Sabino, Marc Ferrante, Séverine Vermeire, Paul Declerck, Debby Thomas
doi : 10.1093/ecco-jcc/jjaa239
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 988–993
Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.
Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index
Gabriel Rahmi, Emmanuel Coron, Guillaume Perrod, Michael Levy, Jacques Moreau, Driffa Moussata, Enrique Perez-Cuadrado-Robles, Antoine Chupin, Lucille Quénéhervé, Arnaud Bourreille, Aude Marchal, Christophe Cellier, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjaa255
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 994–999
Histological healing may represent the ultimate therapeutic goal in ulcerative colitis [UC], but it requires biopsies. Our aim was to develop a non-invasive index able to assess histological disease activity in ulcerative colitis, using probe-based confocal laser endomicroscopy [pCLE].
Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID
A Buisson, J Filippi, A Amiot, G Cadiot, M Allez, P Marteau, Y Bouhnik, G Pineton de Chambrun, A L Pelletier, S Nancey, D Moussata, A Attar, A Blain, L Vuitton, G Vernier-Massouille, P Seksik, M Nachury, J L Dupas, D Laharie, L Peyrin-Biroulet, E Louis, J Y Mary on behalf of the GETAID
doi : 10.1093/ecco-jcc/jjaa250
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1000–1008
Defining and assessing the reproducibility of Crohn’s disease [CD] endoscopic lesions is essential in assessing endoscopic healing.
Luminal Narrowing Alone Allows an Accurate Diagnosis of Crohn’s Disease Small Bowel Strictures at Cross-Sectional Imaging
Daniel Stocker, Michael J King, Maria El Homsi, Guillermo Carbonell, Octavia Bane, Jordan Cuevas, Qingqing Liu, Judy Cho, John T Doucette, Alexander J Greenstein, Jean-Frederic Colombel, Noam Harpaz, Bachir Taouli
doi : 10.1093/ecco-jcc/jjaa256
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1009–1018
Current consensus recommendations define small bowel strictures [SBS] in Crohn’s disease [CD] on imaging as luminal narrowing with unequivocal upstream bowel dilation. The aim of this study was to [1] evaluate the performance of cross-sectional imaging for SBS diagnosis in CD using luminal narrowing with upstream SB dilation and luminal narrowing with or without upstream dilation, and [2] compare the diagnostic performance of computed tomography [CT] and magnetic resonance enterography [MRE] for SBS diagnosis.
Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease
Rebecka Ventin-Holmberg, Anja Eberl, Schahzad Saqib, Katri Korpela, Seppo Virtanen, Taina Sipponen, Anne Salonen, P?ivi Saavalainen, Eija Nissil?
doi : 10.1093/ecco-jcc/jjaa252
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1019–1031
Inflammatory bowel diseases [IBDs], Crohn’s disease [CD] and ulcerative colitis [UC], are globally increasing chronic gastro-intestinal inflammatory disorders associated with altered gut microbiota. Infliximab [IFX], a tumour necrosis factor [TNF]-alpha blocker, is used to treat IBD patients successfully, though one-third of the patients do not respond to therapy. No reliable biomarkers are available for prediction of IFX response. Our aims were to investigate the faecal bacterial and fungal communities during IFX therapy and find predictors for IFX treatment response in IBD patients.
Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis
William Becker, Haider Rasheed Alrafas, Philip B Busbee, Michael D Walla, Kiesha Wilson, Kathryn Miranda, Guoshuai Cai, Vasanta Putluri, Nagireddy Putluri, Mitzi Nagarkatti, Prakash S Nagarkatti
doi : 10.1093/ecco-jcc/jjaa253
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1032–1048
Cannabinoid receptor [CB] activation can attenuate inflammatory bowel disease [IBD] in experimental models and human cohorts. However, the roles of the microbiome, metabolome, and the respective contributions of haematopoietic and non-haematopoietic cells in the anti-colitic effects of cannabinoids have yet to be determined.
Systematic Review of Factors Affecting Transition Readiness Skills in Patients with Inflammatory Bowel Disease
Lara E Johnson, Matthew J Lee, Tamara Turner-Moore, Lydia R Grinsted Tate, Alenka J Brooks, Rachel S Tattersall, Georgina L Jones, Alan J Lobo
doi : 10.1093/ecco-jcc/jjaa245
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1049–1059
The incidence of inflammatory bowel disease [IBD] diagnosed before adulthood is increasing worldwide. Transition from paediatric to adult health care requires certain skills. The aim of this study was to identify factors affecting these skills.
Post-traumatic Growth in Inflammatory Bowel Disease Patients: The Role of Illness Cognitions and Physical Quality of Life
Yaira Hamama-Raz, Shlomit Nativ, Liat Hamama
doi : 10.1093/ecco-jcc/jjaa247
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1060–1067
The symptoms and complications associated with inflammatory bowel disease [IBD] have been found to be associated significantly with impaired health-related quality of life. Nevertheless, there may also be a positive psychological change such as post-traumatic growth, as was noted among patients with other chronic diseases, but this remains understudied in patients with IBD. In this study, we explored associations between post-traumatic growth and illness cognitions (helplessness, acceptance and perceived benefits). In addition, we evaluated whether physical quality of life in IBD patients mediates the link between illness cognitions and post-traumatic growth.
Food Additive Emulsifiers and Their Impact on Gut Microbiome, Permeability, and Inflammation: Mechanistic Insights in Inflammatory Bowel Disease
Aaron S Bancil, Alicia M Sandall, Megan Rossi, Benoit Chassaing, James O Lindsay, Kevin Whelan
doi : 10.1093/ecco-jcc/jjaa254
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1068–1079
The global burden of inflammatory bowel disease [IBD] has increased over the 21st century. Despite multiple studies investigating the pathogenesis of IBD, the causative mechanisms pertaining to its increased prevalence remain unclear. There is growing evidence that aspects of a ‘Western diet’ increase the risk of developing IBD. More recently, evidence implicating dietary emulsifiers has accumulated, with ecological studies showing a positive correlation between inflammatory bowel disease and emulsifier consumption.
Authors’ Reply to: ‘COVID-19 in the IBD Population: The Need for Correct Nomenclature’
Mohamed Attauabi, Jakob Benedict Seidelin, Johan Burisch
doi : 10.1093/ecco-jcc/jjaa240
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Page 1080
Gut Microbiota-Derived Propionate Production May Explain Beneficial Effects of Intermittent Fasting in Experimental Colitis
Junhong Su, Henri Braat, Maikel P Peppelenbosch
doi : 10.1093/ecco-jcc/jjaa248
Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 1081–1082
